913574-95-5 Usage
Description
cis-1-Cbz-3-fluoro-4-hydroxypiperidine is a piperidine derivative featuring a fluorine atom at the third carbon and a hydroxy group on the fourth carbon, both in the cis configuration. cis-1-Cbz-3-fluoro-4-hydroxypiperidine is protected by a carbobenzyloxy (Cbz) group, which can be selectively removed to expose the free amine. Its unique structure and reactivity contribute to its potential as a building block in medicinal chemistry, particularly for the synthesis of pharmaceuticals and bioactive compounds.
Uses
Used in Pharmaceutical Synthesis:
cis-1-Cbz-3-fluoro-4-hydroxypiperidine is utilized as a key intermediate in the synthesis of various pharmaceuticals and bioactive compounds. Its unique structure allows for the development of new drugs with improved efficacy and selectivity.
Used in Medicinal Chemistry Research:
As a valuable tool in medicinal chemistry, cis-1-Cbz-3-fluoro-4-hydroxypiperidine is employed in the design and synthesis of novel compounds with potential therapeutic applications. Its reactivity and structural features enable the exploration of new chemical space and the optimization of drug candidates.
Used in Drug Development:
cis-1-Cbz-3-fluoro-4-hydroxypiperidine serves as a building block in drug development, facilitating the creation of new chemical entities with potential therapeutic benefits. Its unique properties can be leveraged to enhance the pharmacokinetic and pharmacodynamic profiles of drug candidates.
Used in Chemical Synthesis:
In the field of chemical synthesis, cis-1-Cbz-3-fluoro-4-hydroxypiperidine is used as a versatile starting material for the preparation of a wide range of organic compounds. Its reactivity and functional group compatibility make it suitable for various synthetic transformations and the construction of complex molecular architectures.
Check Digit Verification of cas no
The CAS Registry Mumber 913574-95-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,1,3,5,7 and 4 respectively; the second part has 2 digits, 9 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 913574-95:
(8*9)+(7*1)+(6*3)+(5*5)+(4*7)+(3*4)+(2*9)+(1*5)=185
185 % 10 = 5
So 913574-95-5 is a valid CAS Registry Number.
913574-95-5Relevant articles and documents
NOVEL SUBSTITUTED PIPERAZINE AMIDE COMPOUNDS AS INDOLEAMINE 2, 3-DIOXYGENASE (IDO) INHIBITORS
-
, (2020/06/19)
Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.
HETEROARYL PIPERIDINE ETHER ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR
-
Page/Page column 36; 37, (2018/07/29)
The present invention is directed to heteroarylpiperidine ether compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.
6,7-DIHYDRO-5H-PYRROLO[3,4-B]PYRIDIN-5-ONE ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR
-
Paragraph 0202, (2017/07/14)
The present invention is directed to 6,7-dihydro-5H-pyrrolo[3,4-b]pyridine-5-one compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.
